| scholarly article | Q13442814 |
| P50 | author | Edith Sim | Q87441182 |
| P2093 | author name string | Sotiria Boukouvala | |
| P2860 | cites work | Molecular portraits of human breast tumours | Q28032461 |
| Creation of genome-wide protein expression libraries using random activation of gene expression | Q28186394 | ||
| The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies | Q28242320 | ||
| Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues | Q28287383 | ||
| Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos | Q30653855 | ||
| Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2. | Q30954737 | ||
| Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases | Q33246210 | ||
| Connecting transcription to messenger RNA processing | Q33934155 | ||
| Pharmacogenetics of the arylamine N-acetyltransferases. | Q34624647 | ||
| Alternative poly(A) site selection in complex transcription units: means to an end? | Q34630891 | ||
| Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice. | Q38351718 | ||
| The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons | Q39280707 | ||
| Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). | Q40540212 | ||
| Identification of a minimal promoter sequence for the human N-acetyltransferase Type I gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). | Q40639399 | ||
| Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes | Q40669427 | ||
| Directing alternative splicing: cast and scenarios | Q41279355 | ||
| Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells | Q41354095 | ||
| The rat pyruvate carboxylase gene structure. Alternate promoters generate multiple transcripts with the 5'-end heterogeneity | Q42442496 | ||
| Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder | Q42554525 | ||
| N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. | Q43686360 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 343-351 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts | |
| P478 | volume | 96 |
| Q40059601 | Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors |
| Q47636095 | Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype |
| Q26829025 | Arylamine N-acetyltransferase 1: a novel drug target in cancer development |
| Q36788399 | Arylamine N-acetyltransferases. |
| Q26995125 | Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery |
| Q36300809 | Arylamine N-acetyltransferases: what we learn from genes and genomes |
| Q36301606 | Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations |
| Q55447970 | Comparative analysis of xenobiotic metabolising N-acetyltransferases from ten non-human primates as in vitro models of human homologues. |
| Q36328678 | Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism. |
| Q40311100 | Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects |
| Q36726486 | Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck |
| Q36747900 | Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity |
| Q57258718 | Extrahepatic Drug-Metabolizing Enzymes and Their Significance |
| Q35984967 | Folate-Dependent Hydrolysis of Acetyl-Coenzyme A by Recombinant Human and Rodent Arylamine N-Acetyltransferases |
| Q35730604 | Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. |
| Q35956690 | Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1 |
| Q38556530 | Gene-environment interactions in esophageal cancer |
| Q36065578 | Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter |
| Q35973985 | Homologues of xenobiotic metabolizing N-acetyltransferases in plant-associated fungi: Novel functions for an old enzyme family. |
| Q38396102 | Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity |
| Q35911107 | Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. |
| Q36713274 | Influence of genetic factors on toluene diisocyanate-related symptoms: evidence from a cross-sectional study |
| Q33710997 | Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations. |
| Q40305233 | N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice |
| Q54455459 | N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer. |
| Q28388128 | N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk |
| Q46148230 | NAT2 sequence polymorphisms and acetylation profiles in Indians |
| Q35552622 | NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl |
| Q39259079 | Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes |
| Q27011622 | PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 |
| Q92266247 | Population variability of rhesus macaque (Macaca mulatta) NAT1 gene for arylamine N-acetyltransferase 1: Functional effects and comparison with human |
| Q37329162 | Update on the pharmacogenetics of NATs: structural considerations |
| Q35856283 | Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa |
| Q37113839 | Water-soluble mmp-9 inhibitor prodrug generates active metabolites that cross the blood-brain barrier |
| Q35913120 | mRNA transcript diversity creates new opportunities for pharmacological intervention |
Search more.